Kadmon Holdings, Inc. – NYSE:KDMN
Kadmon Holdings stock price today
$9.5
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Kadmon Holdings stock price quarterly change
+0.53%
quarter
Kadmon Holdings stock price yearly change
+97.92%
year
Kadmon Holdings key metrics
Market Cap | N/A |
Enterprise value | 1.82B |
P/E | -13.32 |
EV/Sales | 113.72 |
EV/EBITDA | -16.16 |
Price/Sales | 102.46 |
Price/Book | 122.67 |
PEG ratio | 0.33 |
EPS | -0.70 |
Revenue | 16.08M |
EBITDA | -113.13M |
Income | -120.20M |
Revenue Q/Q | 2901.22% |
Revenue Y/Y | 33.17% |
Profit margin | -747.49% |
Oper. margin | -727.71% |
Gross margin | 93.83% |
EBIT margin | -727.71% |
EBITDA margin | -703.52% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKadmon Holdings stock price history
Kadmon Holdings stock forecast
Kadmon Holdings financial statements
| Dec 2020 | 615K | -27.85M | -4529.76% |
|---|---|---|---|
| Mar 2021 | 563K | -28.37M | -5040.5% |
| Jun 2021 | 197K | -30.34M | -15403.55% |
| Sep 2021 | 14.70M | -33.62M | -228.63% |
| 2021-03-04 | -0.16 | -0.17 |
|---|---|---|
| 2021-05-06 | -0.18 | -0.17 |
| 2021-08-05 | -0.18 | -0.18 |
| 2021-11-04 | -0.2 | -0.2 |
| Dec 2020 | 162710000 | 46.68M | 28.69% |
|---|---|---|---|
| Mar 2021 | 335107000 | 275.90M | 82.33% |
| Jun 2021 | 310280000 | 276.82M | 89.22% |
| Sep 2021 | 304265000 | 290.25M | 95.39% |
| Dec 2020 | -26.4M | -5.39M | 273K |
|---|---|---|---|
| Mar 2021 | -27.53M | -115.39M | 200.52M |
| Jun 2021 | -25.03M | -45.64M | 543K |
| Sep 2021 | -27.81M | 24.74M | 10.01M |
Kadmon Holdings alternative data
| Aug 2023 | 127 |
|---|---|
| Sep 2023 | 127 |
| Oct 2023 | 127 |
| Nov 2023 | 127 |
| Dec 2023 | 127 |
| Jan 2024 | 127 |
| Feb 2024 | 127 |
| Mar 2024 | 127 |
| Apr 2024 | 127 |
| May 2024 | 127 |
| Jun 2024 | 127 |
| Jul 2024 | 127 |
Kadmon Holdings other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2019 | 1470588 | 0 |
| Mar 2020 | 59600 | 0 |
-
What's the price of Kadmon Holdings stock today?
One share of Kadmon Holdings stock can currently be purchased for approximately $9.5.
-
When is Kadmon Holdings's next earnings date?
Unfortunately, Kadmon Holdings's (KDMN) next earnings date is currently unknown.
-
Does Kadmon Holdings pay dividends?
No, Kadmon Holdings does not pay dividends.
-
What is Kadmon Holdings's stock symbol?
Kadmon Holdings, Inc. is traded on the NYSE under the ticker symbol "KDMN".
-
What is Kadmon Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Kadmon Holdings?
Shares of Kadmon Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Kadmon Holdings have?
As Jul 2024, Kadmon Holdings employs 127 workers.
-
When Kadmon Holdings went public?
Kadmon Holdings, Inc. is publicly traded company for more then 9 years since IPO on 27 Jul 2016.
-
What is Kadmon Holdings's official website?
The official website for Kadmon Holdings is kadmon.com.
-
Where are Kadmon Holdings's headquarters?
Kadmon Holdings is headquartered at 450 E 29th St, New York City, NEW YORK.
-
How can i contact Kadmon Holdings?
Kadmon Holdings's mailing address is 450 E 29th St, New York City, NEW YORK and company can be reached via phone at +1 212 308 6000.
Kadmon Holdings company profile:
Kadmon Holdings, Inc.
kadmon.comExchange:
NYSE
Full time employees:
127
Industry:
Biotechnology
Sector:
Healthcare
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.
450 E 29th St
New York City, NEW YORK 10016
New York City, NEW YORK 10016
CIK: 0001557142
ISIN: US48283N1063
CUSIP: 48283N106
